Get the Stockscreener App
5.96
1.81%
-0.11
After Hours:
5.95
-0.010
-0.17%
Neuraxis Inc stock is traded at $5.96, with a volume of 47,233.
It is down -1.81% in the last 24 hours and down -14.98% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$6.07
Open:
$6.01
24h Volume:
47,233
Relative Volume:
0.54
Market Cap:
$74.84M
Revenue:
$4.28M
Net Income/Loss:
$-7.28M
P/E Ratio:
-7.3165
EPS:
-0.8146
Net Cash Flow:
$-6.17M
1W Performance:
-0.67%
1M Performance:
-14.98%
6M Performance:
+2.58%
1Y Performance:
+142.08%
1-Day Range:
$5.935
$6.08
1-Week Range:
$5.72
$6.12
52-Week Range:
$2.21
$9.33
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
5.96 | 78.74M | 4.28M | -7.28M | -6.17M | -0.8146 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuraxis Inc Stock (NRXS) Latest News
Neuraxis Inc. (NRXS) Peer Comparison – Compare with Others - Value Research
Neuraxis Inc. (NRXS) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
NeurAxis Earnings Call Signals High Growth, High Hurdles - TipRanks
NeurAxis Enhances Executive and Director Equity Compensation - TipRanks
Neuraxis (NRXS) grants CEO 199K instantly vesting stock units - Stock Titan
NeurAxis (NRXS) Institutional Ownership 2026 - MarketBeat
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up - NewsBreak: Local News & Alerts
Neuraxis (NRXS) Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Jumps 32%Performance Review - vinanet.vn
NRXS Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 32% Stock SurgeEarnings Per Share - Vinanet
Neuraxis Inc. (NRXS) Q2 2026 Earnings: Narrower Loss Beats Expectations as Stock Holds SteadyStrong Earnings Momentum - vinanet.vn
NRXS Q2 2026 Earnings: 41.79% EPS Beat Signals Cost Discipline, Yet Shares Slip 1.26%Return On Assets - vinanet.vn
NeurAxis revenues up 116% to USD 1.9M in Q2 2026 - Medical Buyer
NeurAxis, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
NeurAxis (NRXS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Could NeurAxis (NASDAQ:NRXS) Reshape Nasdaq Composite Focus? - Kalkine Media
Transcript : NeurAxis, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
NeurAxis (NASDAQ:NRXS): What Could Today’s Update Reveal About Pediatric Therapy Adoption And Reimbursement? - Kalkine Media
NRXS: Q2 revenue up 116% YoY, gross margin at 85.9%, with payer coverage and VA expansion driving growth - TradingView
Earnings call transcript: NeurAxis falls on Q2 2026 EPS miss despite 116% revenue growth - Investing.com
NeurAxis reports 116% revenue growth in second quarter 2026 By Investing.com - Investing.com Nigeria
NeurAxis reports 116% revenue growth in second quarter 2026 - Investing.com
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth - The Manila Times
NRXS: Q2 2026 revenue surged 116% year-over-year, with gross margin up to 85.9% and strong cash position - TradingView
NRXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NeurAxis (NYSE American: NRXS) doubles sales yet warns on going concern - Stock Titan
Earnings To Watch: Neuraxis Inc (NRXS) Q2 2026 -- GF Value Sees 55% Downside - Yahoo Finance
NeurAxis, Inc. (NRXS) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
NeurAxis宣佈爲IB-Stim PENFS療法增加美國中大西洋地區的覆蓋範圍，將服務擴展至超過500,000人 - Moomoo
Neuraxis Expands Payer Coverage for Percutaneous Electrical Nerve Field Stimulation and Ib-Stim Treatment - marketscreener.com
NeurAxis expands insurance coverage for its IB-Stim neuromodulation device, adding 500,000 covered lives. - Pluang
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Neuraxis Q1 2026 Earnings: Narrower-Than-Expected Loss as EPS Beats Consensus by 7.12%Dividend Cut Risk - vinanet.vn
NRXS|Neuraxis Inc|Price:6.735|Chg%:+0.485 - TradingKey
Neuraxis Inc (NRXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRXS Q1 2026 Earnings: Narrower-than-Expected Loss Despite Stock DeclineEPS Estimate Trend - vinanet.vn
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026 - The Manila Times
NeurAxis, Inc. to Report Second Quarter 2026 Financial Results on August 11 and Host Conference Call - Quiver Quantitative
Neuraxis Inc (NRXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuraxis Inc (NRXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuraxis Inc (NRXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuraxis Inc (NRXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NRXS|Neuraxis Inc|Price:6.800| - TradingKey
Neuraxis Inc (NRXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Neuraxis, Inc. Revenue Breakdown – AMEX:NRXS - TradingView
Form S-3 Neuraxis Inc For: 24 July By Investing.com - Investing.com South Africa
Neuraxis Inc. (NRXS) Posts Modest Gains, Testing Key LevelsValue Area High - Vinanet
NRXS Q1 2026 Earnings: EPS Beat as Narrower-Than-Expected Losses Offset by Stock DeclineEarnings Yield Analysis - Vinanet
NRXS Q1 2026 Earnings: Narrower Loss Surprises, but Stock Declines 2.87%Earnings Forecast Report - vinanet.vn
Neuraxis Inc. (NRXS) Q1 2026 Earnings: EPS Beat Despite Negative Bottom Line, Stock SlidesEarnings Season Preview - DonanımHaber
Neuraxis, Inc. Files Form 8-K with SEC: Company Details, Address, and Stock Listing on NYSE American - Minichart
Neuraxis Inc Stock (NRXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neuraxis Inc Stock (NRXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carrico Thomas Joeseph | CRO, CCO, CPO |
Apr 01 '26 |
Buy |
1.96 |
667 |
1,307 |
331,903 |
| Carrico Brian Allen | Chief Executive Officer |
Apr 01 '26 |
Buy |
1.96 |
8,060 |
15,798 |
348,178 |
| Hannasch Brian | 10% Owner |
Feb 12 '26 |
Buy |
4.92 |
40,000 |
196,800 |
1,211,522 |
| Hannasch Brian | 10% Owner |
Feb 11 '26 |
Buy |
4.65 |
40,000 |
186,000 |
1,171,522 |
| Aharon Gil | Director |
Dec 23 '25 |
Buy |
3.52 |
286,138 |
1,007,206 |
286,138 |
0.86%
0.31%
Cap:
|
Volume (24h):